Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Goserelin
Drug ID BADD_D01038
Description Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
Indications and Usage Goserelin is indicated for: - Use in combination with flutamide for the management of locally confined carcinoma of the prostate - Palliative treatment of advanced carcinoma of the prostate - The management of endometriosis - Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding - Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women
Marketing Status approved
ATC Code L02AE03
DrugBank ID DB00014
KEGG ID D04405
MeSH ID D017273
PubChem ID 5311128
TTD Drug ID D00BCG
NDC Product Code 55463-0005; 70720-951; 70720-950
UNII 0F65R8P09N
Synonyms Goserelin | ICI-118630 | ICI 118630 | ICI118630 | Zoladex | Goserelin Acetate | Acetate, Goserelin
Chemical Information
Molecular Formula C59H84N18O14
CAS Registry Number 65807-02-5
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C( CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C 6CCC(=O)N6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Herpes zoster11.05.02.003; 17.09.03.026; 23.11.05.005--
High density lipoprotein decreased13.12.01.003---
Hirsutism05.05.01.005; 23.02.04.001--
Hostility19.05.01.0030.000334%-
Hypercalcaemia05.04.01.002; 14.04.01.003--
Hypercholesterolaemia14.08.01.001---
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis08.01.03.028; 23.02.03.0040.001401%
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertonia15.05.04.007; 17.05.02.001---
Hyperuricaemia14.09.01.003--
Hypotension24.06.03.002--
IIIrd nerve paralysis06.05.02.011; 17.04.02.003---
Immune system disorder10.02.01.001---
Impaired healing08.03.02.0010.000334%-
Incontinence07.01.06.011; 17.05.01.006; 20.02.02.004---
Increased appetite08.01.09.027; 14.03.01.003---
Infection11.01.08.002---
Influenza11.05.03.001; 22.07.02.001---
Injection site bruising08.02.03.042; 12.07.03.042; 23.03.11.015; 24.07.06.0170.003971%-
Injection site erythema08.02.03.001; 12.07.03.001; 23.03.06.0150.001869%-
Injection site haematoma08.02.03.004; 12.07.03.004; 24.07.01.0090.000901%-
Injection site haemorrhage08.02.03.005; 12.07.03.005; 24.07.01.0100.007675%-
Injection site induration08.02.03.007; 12.07.03.0070.000901%-
Injection site irritation08.02.03.027; 12.07.03.027---
Injection site mass08.02.03.009; 12.07.03.0100.001869%-
Injection site pain08.02.03.010; 12.07.03.0110.006674%-
Injection site pruritus08.02.03.013; 12.07.03.014; 23.03.12.0070.001135%-
Injection site reaction08.02.03.014; 12.07.03.0150.001301%
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 12 Pages